Wolden S L, Wara W M, Larson D A, Prados M D, Edwards M S, Sneed P K
University of California, Department of Radiation Oncology, San Francisco 94143-0226, USA.
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9. doi: 10.1016/0360-3016(95)00067-9.
To evaluate the diagnosis, therapy, and survival of patients with intracranial germ-cell tumors. To define the role of prophylactic craniospinal irradiation and chemotherapy necessary to impact on survival.
Forty-eight patients with surgically confirmed or suspected primary intracranial germ-cell tumors treated at UCSF between 1968-1990 were reviewed. Thirty-four patients had a pathologic diagnosis, including 24 germinomas, 3 malignant teratomas, 2 choriocarcinomas, 1 embryonal carcinoma, 1 endodermal sinus tumor, and 3 mixed tumors. Information obtained included histology, location, cerebrospinal fluid (CSF) cytology, alpha-fetoprotein (AFP), and beta-human chorionic gonadotropin (B-HCG), metastatic evaluation, radiation details, survival, and sites of failure. Minimum follow-up time was 2 years and ranged to a maximum of 24 years, with a median of 8 years.
Median age at diagnosis was 16 years with 36 males and 12 females. Ten of 32 patients had elevated B-HCG at diagnosis; 6 of 29 had elevations of AFP. Cerebrospinal fluid cytology was negative in 35 of 36 patients evaluated; myelography or spinal MRI was positive in only 1 of 31 patients studied. Five-year actuarial disease-free survival after irradiation was 91% for germinomas, 63% for unbiopsied tumors, and 60% for nongerminoma germ-cell tumors with doses of 50-54 Gy to the local tumor site with or without whole-brain or whole-ventricular irradiation. Routine prophylactic cranio-spinal axis irradiation was not given with a spinal only failure rate of 2%. Eleven of 48 patients have expired, with an actuarial 5-year survival rate of 100% for germinomas, 79% for nonbiopsied tumors, and 80% for nongerminoma germ-cell tumors.
With complete diagnostic craniospinal evaluation, spinal irradiation is not necessary. Cure rates for germinomas are excellent with irradiation alone. Multidrug chemotherapy is necessary with irradiation for nongerminoma germ-cell tumors. Histology is the most important prognostic factor; therefore, all patients should have surgical conformation of their diagnosis so that appropriate treatment can be given.
评估颅内生殖细胞肿瘤患者的诊断、治疗及生存情况。明确预防性全脑脊髓放疗及化疗对生存的影响作用。
回顾了1968年至1990年间在加州大学旧金山分校接受治疗的48例经手术确诊或疑似原发性颅内生殖细胞肿瘤患者。34例患者有病理诊断,包括24例生殖细胞瘤、3例恶性畸胎瘤、2例绒毛膜癌、1例胚胎癌、1例内胚窦瘤和3例混合性肿瘤。获取的信息包括组织学、肿瘤位置、脑脊液(CSF)细胞学、甲胎蛋白(AFP)和β-人绒毛膜促性腺激素(β-HCG)、转移评估、放疗细节、生存情况及复发部位。最短随访时间为2年,最长达24年,中位随访时间为8年。
诊断时的中位年龄为16岁,男性36例,女性12例。32例患者中有10例在诊断时β-HCG升高;29例中有6例AFP升高。36例接受评估的患者中,35例脑脊液细胞学检查为阴性;31例接受检查的患者中,仅1例脊髓造影或脊柱磁共振成像(MRI)呈阳性。生殖细胞瘤放疗后的5年无病生存率为91%,未活检肿瘤为63%,非生殖细胞性生殖细胞肿瘤为60%,局部肿瘤部位给予50 - 54 Gy剂量放疗,可联合或不联合全脑或全脑室放疗。未进行常规预防性全脑脊髓轴放疗,脊髓单独复发率为2%。48例患者中有11例死亡,生殖细胞瘤的5年精算生存率为100%,未活检肿瘤为79%,非生殖细胞性生殖细胞肿瘤为80%。
通过完整的诊断性全脑脊髓评估,无需进行脊髓放疗。单纯放疗对生殖细胞瘤的治愈率很高。非生殖细胞性生殖细胞肿瘤放疗时需要联合多药化疗。组织学是最重要的预后因素;因此,所有患者均应通过手术确诊,以便给予适当治疗。